Showing results (111-120 of 154) with videos related to
Sort By:
Pageof 16
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 14, 2007
Influence of mustard group structure on pathways of in vitro metabolism of anticancer N-(2-hydroxyethyl)-3,5-dinitrobenzamide 2-mustard prodrugsNuala A Helsby, Michael A Goldthorpe, Magdalene H Y Tang, et al.BMC Cancer|October 27, 2012
PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumoursMark J McKeage, Michael B Jameson, Ramesh K Ramanathan, et al.Journal of Medicinal Chemistry|March 1, 2007
Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapyGraham J Atwell, Shangjin Yang, Frederik B Pruijn, et al.Bioorganic & Medicinal Chemistry|June 29, 2010
Hypoxic selectivity and solubility--investigating the properties of A-ring substituted nitro seco-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-ones (nitroCBIs) as hypoxia-activated prodrugs for antitumor therapyMoana Tercel, Shangjin Yang, Graham J Atwell, et al.Biochemical Pharmacology|August 19, 2014
Identification of one-electron reductases that activate both the hypoxia prodrug SN30000 and diagnostic probe EF5Jingli Wang, Chris P Guise, Gabi U Dachs, et al.Organic & Biomolecular Chemistry|April 17, 2014
Characterisation of radicals formed by the triazine 1,4-dioxide hypoxia-activated prodrug, SN30000Robert F Anderson, Pooja Yadav, Deepa Patel, et al.Journal of Medicinal Chemistry|May 16, 2003
Unsymmetrical DNA cross-linking agents: combination of the CBI and PBD pharmacophoresMoana Tercel, Stephen M Stribbling, Hilary Sheppard, et al.Cancer Research|April 16, 2009
DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicityRachelle S Singleton, Christopher P Guise, Dianne M Ferry, et al.Bioorganic & Medicinal Chemistry|July 22, 2011
N-alkylated cyclen cobalt(III) complexes of 1-(chloromethyl)-3-(5,6,7-trimethoxyindol-2-ylcarbonyl)-2,3-dihydro-1H-pyrrolo[3,2-f]quinolin-5-ol DNA alkylating agent as hypoxia-activated prodrugsGuo-Liang Lu, Ralph J Stevenson, John Yu-Chih Chang, et al.Cancer Biology & Therapy|April 15, 2015
Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinomaMaria R Abbattista, Stephen M F Jamieson, Yongchuan Gu, et al.Pageof 16